VistaGen Therapeutics, Inc. (VTGN)
Automate Your Wheel Strategy on VTGN
With Tiblio's Option Bot, you can configure your own wheel strategy including VTGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTGN
- Rev/Share 0.0187
- Book/Share 1.2057
- PB 0.4568
- Debt/Equity 0.028
- CurrentRatio 4.6748
- ROIC -1.3308
- MktCap 18051218.0
- FreeCF/Share -1.4298
- PFCF -0.2989
- PE -0.347
- Debt/Assets 0.0219
- DivYield 0
- ROE -1.0973
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | VTGN | Jefferies | Buy | Hold | -- | $0.9 | Dec. 17, 2025 |
| Downgrade | VTGN | Maxim Group | Buy | Hold | -- | -- | Dec. 17, 2025 |
| Downgrade | VTGN | Stifel | Buy | Hold | -- | $1 | Dec. 17, 2025 |
| Downgrade | VTGN | William Blair | Outperform | Market Perform | -- | -- | Dec. 17, 2025 |
News
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
Published: February 22, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 19, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 16, 2026.
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
Published: February 17, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. So what: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
Published: February 17, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”), of the important March 16, 2026 lead plaintiff deadline.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 16, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Vistagen (VTGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of Mar. 16, 2026.
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 16, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 16, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 16, 2026.
Read More
VTGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
Published: February 16, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - February 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vistagen Therapeutics, Inc. ("Vistagen" or …
Read More
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors
Published: February 16, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 16, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Vistagen Therapeutics, Inc., (“Vistagen” or the "Company") (NASDAQ: VTGN) investors off a class action on behalf of investors that bought securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”). Vistagen investors have until March 16, 2026 to file a lead plaintiff motion.
Read More
VTGN Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Class Action
Published: February 13, 2026 by: GlobeNewsWire
Sentiment: Neutral
Robbins LLP is Investigating Allegations that Vistagen Therapeutics, Inc. (VTGN) Misled Investors Regarding the Viability of its Trial Study of Fasedieno
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 13, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 16, 2026.
Read More
VTGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
Published: February 11, 2026 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: …
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) between April 1 , 202 4 and December 16 , 202 5, inclusive. Should You Join The Vistagen Class Action Lawsuit?
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 16, 2026.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Vistagen (VTGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of Mar. 16, 2026.
Read More
VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel
Published: February 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover losses for investors under the federal securities laws.
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (“Vistagen” or “the Company”) (NASDAQ: VTGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before March 16, 2026.
Read More
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
Published: February 05, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Vistagen Therapeutics urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 3/16/2026
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
Published: February 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) between April 1 , 202 4 and December 16 , 202 5, inclusive. Should You Join The Vistagen Class Action Lawsuit?
Read More
ROSEN, A LEADING LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
Published: February 04, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
March 16, 2026 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTGN
Published: February 04, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vistagen investors who were adversely affected by alleged securities fraud between April 1, 2024 and December 16, 2025.
Read More
VTGN INVESTOR ALERT -- LEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS
Published: February 04, 2026 by: PRNewsWire
Sentiment: Neutral
VTGN INVESTOR ALERT — March 16, 2026 DEADLINE NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) of a pending securities class action and the upcoming lead plaintiff deadline. Lead Plaintiff Deadline: March 16, 2026 Class Period: April 1, 2024 through December 16, 2025 Submit your information to join this case or contact Joseph E.
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
Published: February 04, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN
Published: February 03, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - February 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
Published: February 02, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline. So what: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: February 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Vistagen Therapeutics urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 3/16/2026
Read More
Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Class Action Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
Published: January 30, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options
Read More
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Published: January 29, 2026 by: GlobeNewsWire
Sentiment: Neutral
New class action for Vistagen Therapeutics urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 3/16/2026
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
Published: January 28, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options
Read More
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Vistagen Therapeutics Class Action Lawsuit?
Read More
About VistaGen Therapeutics, Inc. (VTGN)
- IPO Date 2011-06-21
- Website https://www.vistagen.com
- Industry Biotechnology
- CEO Shawn K. Singh
- Employees 48